Literature DB >> 36120489

Immunotherapy biomarkers for HCC: contemporary challenges and emerging opportunities.

Sandi Kwee1,2, Xin Chen1.   

Abstract

Entities:  

Year:  2022        PMID: 36120489      PMCID: PMC9480975          DOI: 10.20517/2394-5079.2022.58

Source DB:  PubMed          Journal:  Hepatoma Res        ISSN: 2394-5079


× No keyword cloud information.
  12 in total

1.  Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.

Authors:  Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2018-06-03       Impact factor: 41.316

2.  Multiomics identifies the link between intratumor steatosis and the exhausted tumor immune microenvironment in hepatocellular carcinoma.

Authors:  Hiroki Murai; Takahiro Kodama; Kazuki Maesaka; Shoichiro Tange; Daisuke Motooka; Yutaka Suzuki; Yasuyuki Shigematsu; Kentaro Inamura; Yoshihiro Mise; Akio Saiura; Yoshihiro Ono; Yu Takahashi; Yota Kawasaki; Satoshi Iino; Shogo Kobayashi; Masashi Idogawa; Takashi Tokino; Tomomi Hashidate-Yoshida; Hideo Shindou; Masanori Miyazaki; Yasuharu Imai; Satoshi Tanaka; Eiji Mita; Kazuyoshi Ohkawa; Hayato Hikita; Ryotaro Sakamori; Tomohide Tatsumi; Hidetoshi Eguchi; Eiichi Morii; Tetsuo Takehara
Journal:  Hepatology       Date:  2022-05-14       Impact factor: 17.425

3.  Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.

Authors:  Ann-Lii Cheng; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Ho Yeong Lim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Ning Ma; Alan Nicholas; Yifan Wang; Lindong Li; Andrew X Zhu; Richard S Finn
Journal:  J Hepatol       Date:  2021-12-11       Impact factor: 25.083

4.  Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.

Authors:  Alexander R Abbas; Marina Ruiz de Galarreta; Yinghui Guan; Andrew X Zhu; Shan Lu; Hartmut Koeppen; Wenjun Zhang; Chih-Hung Hsu; Aiwu Ruth He; Baek-Yeol Ryoo; Thomas Yau; Ahmed O Kaseb; Adam M Burgoyne; Farshid Dayyani; Jessica Spahn; Wendy Verret; Richard S Finn; Han Chong Toh; Amaia Lujambio; Yulei Wang
Journal:  Nat Med       Date:  2022-06-23       Impact factor: 87.241

5.  Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.

Authors:  Anthony B El-Khoueiry; Bruno Sangro; Thomas Yau; Todd S Crocenzi; Masatoshi Kudo; Chiun Hsu; Tae-You Kim; Su-Pin Choo; Jörg Trojan; Theodore H Welling; Tim Meyer; Yoon-Koo Kang; Winnie Yeo; Akhil Chopra; Jeffrey Anderson; Christine Dela Cruz; Lixin Lang; Jaclyn Neely; Hao Tang; Homa B Dastani; Ignacio Melero
Journal:  Lancet       Date:  2017-04-20       Impact factor: 79.321

6.  Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates.

Authors:  Zobair Younossi; Maria Stepanova; Janus P Ong; Ira M Jacobson; Elisabetta Bugianesi; Ajay Duseja; Yuichiro Eguchi; Vincent W Wong; Francesco Negro; Yusuf Yilmaz; Manuel Romero-Gomez; Jacob George; Aijaz Ahmed; Robert Wong; Issah Younossi; Mariam Ziayee; Arian Afendy
Journal:  Clin Gastroenterol Hepatol       Date:  2018-06-14       Impact factor: 11.382

Review 7.  Tumor-Intrinsic Mechanisms Regulating Immune Exclusion in Liver Cancers.

Authors:  Katherine E Lindblad; Marina Ruiz de Galarreta; Amaia Lujambio
Journal:  Front Immunol       Date:  2021-04-26       Impact factor: 7.561

8.  Immunotherapy of hepatocellular carcinoma with infection of hepatitis B or C virus.

Authors:  Cecilia Monge Bonilla; Nicole A McGrath; Jianyang Fu; Changqing Xie
Journal:  Hepatoma Res       Date:  2020-10-12

9.  NASH limits anti-tumour surveillance in immunotherapy-treated HCC.

Authors:  Dominik Pfister; Nicolás Gonzalo Núñez; Roser Pinyol; Olivier Govaere; Matthias Pinter; Marta Szydlowska; Revant Gupta; Mengjie Qiu; Aleksandra Deczkowska; Assaf Weiner; Florian Müller; Ankit Sinha; Ekaterina Friebel; Thomas Engleitner; Daniela Lenggenhager; Anja Moncsek; Danijela Heide; Kristin Stirm; Jan Kosla; Eleni Kotsiliti; Valentina Leone; Michael Dudek; Suhail Yousuf; Donato Inverso; Indrabahadur Singh; Ana Teijeiro; Florian Castet; Carla Montironi; Philipp K Haber; Dina Tiniakos; Pierre Bedossa; Simon Cockell; Ramy Younes; Michele Vacca; Fabio Marra; Jörn M Schattenberg; Michael Allison; Elisabetta Bugianesi; Vlad Ratziu; Tiziana Pressiani; Antonio D'Alessio; Nicola Personeni; Lorenza Rimassa; Ann K Daly; Bernhard Scheiner; Katharina Pomej; Martha M Kirstein; Arndt Vogel; Markus Peck-Radosavljevic; Florian Hucke; Fabian Finkelmeier; Oliver Waidmann; Jörg Trojan; Kornelius Schulze; Henning Wege; Sandra Koch; Arndt Weinmann; Marco Bueter; Fabian Rössler; Alexander Siebenhüner; Sara De Dosso; Jan-Philipp Mallm; Viktor Umansky; Manfred Jugold; Tom Luedde; Andrea Schietinger; Peter Schirmacher; Brinda Emu; Hellmut G Augustin; Adrian Billeter; Beat Müller-Stich; Hiroto Kikuchi; Dan G Duda; Fabian Kütting; Dirk-Thomas Waldschmidt; Matthias Philip Ebert; Nuh Rahbari; Henrik E Mei; Axel Ronald Schulz; Marc Ringelhan; Nisar Malek; Stephan Spahn; Michael Bitzer; Marina Ruiz de Galarreta; Amaia Lujambio; Jean-Francois Dufour; Thomas U Marron; Ahmed Kaseb; Masatoshi Kudo; Yi-Hsiang Huang; Nabil Djouder; Katharina Wolter; Lars Zender; Parice N Marche; Thomas Decaens; David J Pinato; Roland Rad; Joachim C Mertens; Achim Weber; Kristian Unger; Felix Meissner; Susanne Roth; Zuzana Macek Jilkova; Manfred Claassen; Quentin M Anstee; Ido Amit; Percy Knolle; Burkhard Becher; Josep M Llovet; Mathias Heikenwalder
Journal:  Nature       Date:  2021-03-24       Impact factor: 49.962

10.  The paradox of immunotherapy in NASH-HCC.

Authors:  Yao Peng; Chi Chun Wong; Jun Yu
Journal:  Signal Transduct Target Ther       Date:  2021-06-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.